Evaluation of mood disorder questionnaire positivity and associated factors in a population-based screening study

• Autor(a) principal: Konuk,Numan
• Data de Publicação: 2022
• Outros Autores: Karaahmet,Elif, Angın,Ülkem, Kılıç,Alperen, Kökrek,Zekeriya
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Psicologia (Universidade Federal do Rio Grande do Sul. Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-79722022000100220
• topic: Bipolar disorders; Epidemiology; Mood disorders questionnaire; Population-based study; Turkish people

ABSTRACT The Mood Disorders Questionnaire (MDQ) is a 3-item scale that is frequently used in bipolar disorders (BD) screening and questions the symptoms of BD, its effect on functionality, and the coexistence of symptoms. The aim of this study is to evaluate the prevalence of positive screening of the MDQ among general population and to investigate the associated risk factors. In this cross-sectional study, the sample was randomly selected from household data to represent the city population. A total of 432 participants were asked to fill in MDQ, CAGE (cutting down, annoyance by criticism, guilty feeling, and eye-openers) questionnaire, which consists of four clinical interview questions proven to aid in the diagnosis of alcoholism, and clinical and sociodemographic data form. The Cronbach’s alpha value of our current study was 0.813 for MDQ. The prevalence of MDQ positivity was found 7.6%. The estimated prevalence rate of bipolar disorders varied between 0.3 and 13.4% according to different cut-off values. Multivariate logistic regression models showed that the presence of possible alcohol addiction, shift work history, and body mass index (BMI) were statistically significant predictors of MDQ positivity. The prevalence of MDQ positivity found is similar to studies in literature. Keeping in mind that psychometric properties of the MDQ, positive screen results should be cautiously interpreted due to the presence of other risk factors and comorbidities.